Entasis Therapeutics Holdings Inc.
ETTX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ETTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Mar 31, 2022.
Tracking 3 pipeline candidates for Entasis Therapeutics Holdings Inc..
Run Entasis Therapeutics Holdings Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Entasis Therapeutics Holdings Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
7.7 months
D/E 1.65
Lead: Phase 3
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Frequently asked questions
What is Entasis Therapeutics Holdings Inc.'s lead drug candidate?
Entasis Therapeutics Holdings Inc.'s most advanced tracked candidate is etx0282cpdp (Phase 1) for complicated urinary tract infections (cUTIs).
Who is the CEO of Entasis Therapeutics Holdings Inc.?
Manoussos Perros, Ph.D. is the chief executive officer of Entasis Therapeutics Holdings Inc. (ETTX).
What therapeutic areas does Entasis Therapeutics Holdings Inc. focus on?
Entasis Therapeutics Holdings Inc. develops therapies across Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.